Fabry disease is a rare genetic disorder caused by a defect in the GLA gene. The defect causes a deficiency in a specific enzyme needed to break down fats; the resulting fat accumulation leads to cell damage, with consequences such as kidney failure, heart attack and stroke.

Currently, screening for Fabry disease relies on measuring levels of alpha-Gal A activity in a specific type of white blood cell, but recent findings suggest an easier method for screening and diagnosis.

Fabry disease: dried blood spot testing

According to data published by Japanese researchers in the Journal of Human Genetics, the analysis of dried blood spots (DBS) may help diagnose Fabry disease and initiate early treatment in high-risk patients with cardiac, renal, or neurological symptoms.

Due to its rarity, Fabry disease is both underdiagnosed and misdiagnosed by clinicians; however, the DBS test could potentially be an effective and simple method to not only identify Fabry disease in high-risk patients but also prevent serious complications.

GlobalData epidemiologists present the diagnosed prevalent cases of Fabry disease in the seven major pharmaceutical markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan), shown alongside Fabry disease cases that experienced a cardiovascular complication such as a mini-stroke (transient ischemic attack) or stroke (as shown in Figure 1).

Taking into consideration all high-risk populations and not only cardiovascular, the proportion of high-risk cases within Fabry disease will likely increase with the implementation of this new screening method, as well as result in an increase in overall diagnosed prevalent cases of Fabry disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related reports

GlobalData (2015). EpiCast Report: Fabry Disease – Epidemiology Forecast to 2024, August 2015, GDHCER086-15


GlobalData (2015). OpportunityAnalyzer: Fabry Disease – Opportunity Analysis and Forecast to 2024, August 2015, GDHC039POA